Literature DB >> 12963454

Spectrophotometric studies and applications for the determination of yttrium in pure and in nickel base alloys.

A S Amin1, T Y Mohammed, A A Mousa.   

Abstract

Yttrium reacts with 5-(4'-chlorophenylazo)-6-hydroxypyrimidine-2,4-dione (I), 5-(2'-bromophenylazo)-6-hydroxypyrimidine-2,4-dione (II), 5-(2',4'-dimethylphenylazo)-6-hydroxypyrimidine-2,4-dione (III), 5-(4'-nitro-2',6'-dichlorophenylazo)-6-hydroxypyrimidine-2,4-dione (IV), 5-(2'-methyl-4'-hydroxyphenylazo)-6-hydroxypyrimidine-2,4-dione (V) to form a dark pink complexes, having an absorption maximum at 610, 577, 596, 567 and 585 nm, respectively. The complex formation was completed spontaneously in theil buffer solution and the resulting complex was stable for at least 3 h after dilution. Under the optimum conditions employed, the molar absorptivities were found to be 1.60 x 10(4), 1.29 x 10(4), 1.96 x 10(4), 1.45 x 10(4) and 1.21 x 10(4) l mol(-1) cm(-1) and the molar ratios were (1:1) and (1:2) (M:L). The linear ranges were found within 95 microg of yttrium in 25 ml solution. One of the characteristics of the complex was its high tolerance for calcium and hence a method of separation and enrichment of microamounts of yttrium by using calcium oxalate precipitate was developed and applied to measure yttrium in nickel-base alloys. Interfering species and their elimination have been studied. The precision and recovery are both satisfactory.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12963454     DOI: 10.1016/s1386-1425(03)00040-4

Source DB:  PubMed          Journal:  Spectrochim Acta A Mol Biomol Spectrosc        ISSN: 1386-1425            Impact factor:   4.098


  1 in total

1.  Crystal structure, characterization and Hirshfeld analysis of bis-{(E)-1-[(2,4,6-tri-bromo-phen-yl)diazen-yl]naphthalen-2-olato}copper(II) dimethyl sulfoxide monosolvate.

Authors:  Souheyla Chetioui; Hassiba Bougueria; Ouarda Brihi; Mehdi Boutebdja; Nadia Bouroumane; Hocine Merazig; Rachid Touzani
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2020-02-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.